Objective: Prostate inflammation is one of pathophysiology of prostate hyperplasia in benign prostatic hyperplasia (BPH). There are several factor that involved in prostatic inflammation, such as prostate specific antigen (PSA) that play a role as an autoantigen. The objective of this study was to assess the correlation between free PSA level with prostate histologic aggressiveness, and also the correlation between prostate histologic aggressiveness with prostatic volume in BPH patients. Material & Methods: The design of this study was cross-sectional analytic observational study to determine correlation between serum PSA level with prostatic aggressiveness, and prostatic volume with prostatic aggressiveness. This study was performed from June to November 2016 in Sanglah Public Hospital, Surya Husadha, Balimed, Bhakti Rahayu, and Ganesa Hospital. Eighty three patients with BPH undergoing transurethral resection of the prostate (TURP) were recruited. Results: The result of gamma correlation analysis using Chi-square of PSA level with aggressiveness (p=0.000) and aggressiveness with prostatic volume (p=0.012). Conclusion: Serum PSA level were correlated with prostatic aggressiveness. Prostatic aggressiveness also correlated with prostatic volume.
Prostate specific antigen, prostatic volume, aggressiveness
Izmirli M, Arikan B, Bayazit Y. Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men. Asian Pac J Cancer Prev. 2011; 12: 731-3.
Parsons JK, Bergstrom J, Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int. 2008; 101: 313–8.
Duarsa GWK, Lesmana R, Mahadewa TGB. High serum prostate specific antigen as a risk factor for moderate-severe prostate inflammation in patient with benign prostatic hyperplasia. Bali Med J. 2016; 4: 148-51.
Robert G, Descazeaud A, Allory Y, Vacherot F, de la Taille A. Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? Eur Urol. 2009; (Suppl 8): 879–86.
Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol. 1997; 157: 1301-3.
Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2005; 174(6): 2274-5.
Hofner K, Burkart M, Jacob G. Safety and efficacy of tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. World J Urol. 2007; 25(6): 627-33.
Kwon YK, Seo KW, Park CH, Chang HS, Kim BH, Kim CI. The effect of intraprostatic chronic inflammation on benign prostatic hyperplasia treatment. Korean J Urol. 2010; 51: 266-70.
Gandaglia G, Briganti A, Gontero. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013; 112: 432–41.
Roehrborn CG, Mc Connell JD. Benign prostatic hyperplasia: Etiology, pathophysiology, epidemiology, and natural history. In: Campbell-Walsh Urology, 9th Ed. Chapter 86. Philadelphia: Elseviers; 2007.
Tezval H, Rettkowski A, Herrmann T, Kuczyk M. 504 quantification of the three ring model of T Hald in 455 BPH patients. Eur Urol. 2010; Suppl 9: 176.
Michaud M, Balardy L, Moulis G. Proinflammatory cytokines, aging, and age related diseases. JAMDA. 2013; 30: 1-6.
Lamb AD, Qadam M, Robert S. CD4+ and CD8+ T-lymphocyte scores can not reliably predict progression in patients with benign prostatic hyperplasia. BJU Int. 2011; 108: 43-50.
Putra IBOW, Hamid ARAH, Mochtar CA, Umbas R. Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia. Prostate Int. 2016; 42: 43-48.